In the uterus, oxytocin’s job is settled and used in medicine every day. In the brain, what it does is one of the most argued questions in behavioural research.
Oxytocin · Hypothalamic nine-residue peptide hormone
The same chemical signal can mean different things in different tissues, because what matters is where its receptor sits. Oxytocin receptors are found in the uterus and breast, and also across brain regions involved in social behaviour. Researchers study the brain side to ask what a hormone of labour does there. The obstetric evidence is human and established; the behavioural evidence is human but contested.
Oxytocin is a peptide of nine amino acids, made by neurons in the hypothalamus and released from the posterior pituitary into the blood, and also released within the brain itself. It acts on one receptor, the oxytocin receptor, a G protein-coupled receiver expressed in uterine muscle, the milk-secreting tissue of the breast, and in several brain regions (Gimpl and Fahrenholz, 2001). Oxytocin acetate is the peptide as its acetate salt, the usual form of the synthetic material.
Its peripheral actions are uterine contraction and milk let-down. Its central actions are the research question: receptor mapping in animals shows oxytocin signalling in circuits involved in social recognition and parental behaviour, and the hypothesis is that similar signalling shapes social processing in people. As a curiosity, oxytocin was the first peptide hormone to be chemically synthesised, in 1953 (du Vigneaud et al., 1953).
The established use is obstetric. Synthetic oxytocin given by intravenous infusion or intramuscular injection is a standard medicine for inducing or augmenting labour and for preventing bleeding after birth. Cochrane reviews have pooled randomised trials in women at term: intravenous oxytocin alone for cervical ripening and induction (Alfirevic et al., 2009) and prophylactic oxytocin in the third stage of labour to reduce postpartum blood loss (Westhoff et al., 2013). In Australia it is a Schedule 4 prescription medicine used in hospitals.
The behavioural literature is separate. Since the early 2000s, hundreds of experiments have given intranasal oxytocin to healthy adults, and to people with autism or psychiatric diagnoses, and measured tasks of trust, emotion recognition or social attention, sometimes with brain imaging. Early headline findings did not replicate reliably. Leng and Ludwig argued that the amount of intranasally applied peptide reaching the brain is doubtful (Leng and Ludwig, 2016), and Walum and colleagues showed that the typical study sizes leave the field with low statistical power and an inflated share of false positives (Walum et al., 2016). The field continues, with larger and pre-registered designs.
For the brain research, the basic delivery question is open: whether and how much intranasal oxytocin crosses into the human brain, and whether effects seen are central or driven by the hormone acting elsewhere. The behavioural findings are inconsistent across populations, tasks and laboratories, so no claim about trust, bonding or calm is established. The obstetric evidence concerns registered oxytocin medicines given under monitoring in labour; it does not describe other routes, other populations or the material supplied as a research reagent. Oxytocin in the blood is cleared within minutes, which also limits what a single measurement can show.
Oxytocin is listed in Schedule 4 (prescription only) of the Australian Poisons Standard (June 2026), and registered oxytocin injections are used in Australian obstetric care. The material supplied by Pulse is not a registered medicine.
Sources and status checked 2026-09-22
Oxytocin — sizes and pricing